FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: NanoSphere Health Sciences, Inc. (the “Issuer”).

Trading Symbol: NSHS

Number of Outstanding Listed Securities: 108,355,051

Date: February 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
2. The term “Issuer” includes the Issuer and any of its subsidiaries.
3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

1. *Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.*

The Company furthered it’s progress in February on commercializing the sale of products developed utilizing its patented NanoSphere Delivery SystemTM. Final stages of development of the Intra-oral product and Intra-nasal product were completed and the devices necessary for delivery finalized.

The Company continues to grow the sales of the proven Evolve NanoSerum transdermal product in Colorado and the growth in the sales of the CBD- NanoSerum product for Colorado continues to see strong demand.

Vertical Companies in California completed the first production run of the NanoSerum Transdermal product and are now ready to deliver to California Dispensaries the NanoSerum Transdermal product in March once a final compliance review is completed.

NanoSphere Health Sciences, Inc. in November established a new subsidiary in Canada called NanoSphere Cannabis International Inc. (NCI) based in British Columbia. NCI is responsible for overseeing the Licensing of the NanoSphere Delivery SystemTM in Canada and for seeking international license opportunities globally outside the United States. NanoSphere through NCI completed the Master License agreement with Delta 9 in January and Delta 9 received preliminary approval from Health Canada for the first of a number of products to be introduced to the Canadian market in 2019. NCI has already begun discussions on an international basis with entities in Mexico, Germany and Australia. Resulting from these discussions, the Company received in February its first export order for CBD Hemp products from Abba Imports in Mexico. This initial order is for 60,000 units, subject to registration of the Evolve Formulas CBD Hemp transdermal NanoSerum by the Mexico Federal Commission for the Protection Against Sanitary Risks.

In the United States, the Company in February signed a Memorandum of Understanding with 4Evergrn, LLC of Oklahoma for a license agreement of the Evolve Formulas products and entered into a license agreement with Cascade Pure, LLC to license the Evolve Formulas products in Oregon utilizing the NanoSphere Delivery System. We expect products to become available in the Oregon market within 90 days. Additional licensing opportunities are under negotiations for additional States including Florida and Michigan.

The Company has developed a number of new products to be launched as well as expansion opportunities in new territories. To support these expansions, the Company announced in mid November a Capital Raise for $2,250,000 CDN. In December, the Company raised approximately $1,336,000 CDN. In February, the Company closed the final tranche of the raise of approximately $2,000,000 CDN, with the total gross proceeds approximating $3,336,000.

Additionally, the Company has identified a qualified copacker to be used for its line of hemp based products that can be sold nationally and globally. This copacker is GMP and OTC certified and is capable of providing 100,000 units a month of the Company’s new product line.

\*Note -- Regarding any sales projections, in providing financial statements under International Financial Reporting Standards -- revenues, units, and gross profit will be recorded on a calendar year basis. However, as a practical matter, it does not represent what a full year is defined as under our operations. Under our operations, because we bring in licensees and various products at various times in the year, the first year will begin the month that the SKUs are actually in production and ready for sale in the existing licensed states. For example, in California, we’ll begin in October, so the first month of its production and revenue year will begin in October 2018 and will go through October 2019. This presentation provides a more accurate revenue growth, from an operations perspective, that we expect to achieve in each of the various states and each additional new states as well as Canada.

1. *Provide a general overview and discussion of the activities of management.*

Management supervised and assisted in the activities set out in item 1, Additionally, as a biotechnology company, with proven and patented delivery systems for a multiple of industries, the development and licensing of the Company’s products to third parties requires a lot of detailed attention to assure that the Company’s technology and patents are being adhered to precisely. This includes the formulation, the manufacturing, the filling, and therefore the application on a retail basis. The full monetization of the Company’s patented technologies can be a slow and time-consuming process. Management expects operations to expand into various parts the Unites States, Canada, and internationally to be in full motion, in the first quarter of 2019 and has seen further progress during the month of February.

The Company’s wholly owned subsidiary in Canada, NCI, was very active during January with the completion of the Delta 9 agreement and announced February 6, 2019 it’s first order of the company’s CBD Hemp product with Abba Imports in Mexico.

1. *Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.*

The Issuer continues to develop and refine the intranasal and intraoral lines of the Evolve NanoSerumTM product, which is expected to be ready for market in January 2019.

1. *Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.*

not applicable.

1. *Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.*

See item 1.

1. *Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.*

not applicable.

1. *Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.*

See Item 1.

1. *Describe the acquisition of new customers or loss of customers.*

See Item 1.

1. *Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.*

not applicable.

1. *Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.*

See Item 1.

1. *Report on any labour disputes and resolutions of those disputes if applicable.*

not applicable.

1. *Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.*

not applicable.

1. *Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.*

not applicable

1. *Provide details of any securities issued and options or warrants granted.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Security** | **Number Issued** | **Details of Issuance** | **Use of Proceeds(1)** |
| Common shares | 6,666,394 | Private Placement at $0.30 | $1,999,918 for Working Capital |
| Common shares | 121,325 | Shares issued for corporate advisory service |  |
|  |  |  |  |

1. *State aggregate proceeds and intended allocation of proceeds.*
2. *Provide details of any loans to or by Related Persons.*

not applicable.

1. *Provide details of any changes in directors, officers or committee members.*

not applicable.

1. *Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.*

The Issuer is not aware of any trends that are outside the ordinary course of business which would have an impact generally experienced by other companies engaged in the same business or industry.

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 12, 2019 .

 Robert Sutton
Name of Director or Senior Officer

 *“Robert Sutton”*
Signature

Chief Executive Officer
Official Capacity

 Jim Ewing
Name of Director or Senior Officer

 *“Jim Ewing”*
Signature

Controller
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***Name of IssuerNanoSphere Health Sciences Inc. | For Month End2019 February | Date of Report(YY/MM/DD)2019/03/12 |
| Issuer Address#1130 – 5445 DTC Parkway |
| City/Province/Postal CodeGreenwood Village, CO, USA 80111 | Issuer Fax No.( ) | Issuer Telephone No.(720) 845-1465 |
| Contact NameDavid Sutton | Contact PositionPresident | Contact Telephone No.(720) 845-1480 |
| Contact Email Addressdsutton@nanospherehealth.com | Web Site Addresswww.nanospherehealth.com |